September 20, 2013 – Indi Molecular, which pioneered a synthetic replacement for antibodies, today announced that it has raised a $1.5 million seed round led by InterWest Partners and joined by several angel investors. The funds will be used to further develop PCC (protein catalyzed capture) agent technology: a breakthrough process that produces synthetic peptide molecules capable of binding interactions that are equivalent or superior to molecular antibodies. PCCs have several advantages over antibodies, including lower cost, faster development and greater specificity. They are being developed as a replacement for antibodies in in vivo imaging, therapeutics, in vitro diagnostics and biological tools. Indi Molecular, previously an operating division of Integrated Diagnostics (Indi), will now operate as an independent company, while maintaining close ties with its parent company.
Read MorePuget Sound Business Journal | 4 January 2013 |
Patti Payne “Dr. Leroy ‘Lee’ Hood, co-founder and president of the Seattle-based Institute for Systems Biology, has been chosen to receive the highest award bestowed upon scientists by the United States government: the National Medal of Science.” Full Article [subscription required]
Press Release | 13 June 2012
SEATTLE – Integrated Diagnostics (InDi®), an emerging leader in molecular diagnostics, today announced that the company has launched a new operating division, InDi Imaging™, that is creating a new generation of PET imaging probes using the company’s innovative protein catalyzed capture (PCC) agent technology. PCCs, initially developed for in vitro molecular diagnostics, will be employed as rationally designed, in vivo diagnostic imaging probes that mimic the properties of antibodies and biologics in PET molecular imaging, with the benefit of being chemically stable, synthetic small-molecules.
Read MoreXconomy | 13 June 2012 |
Luke Timmerman “This is like going from black and white with no sound to Technicolor and surround sound. It’s big.” Dr. Albert A Luderer, CEO, Integrated Diagnostics.
Technology Review | 22 February 2012 | Full Article
Read MoreProteoMonitor / GenomeWeb | 23 December 2011 | Adam Bonislawski [subscription required]
Read MorePress Release | 16 December 2011
SEATTLE — Integrated Diagnostics announced today that researchers from the company and the California Institute of Technology (Caltech) will receive a Point-of-Care Diagnostics grant through Grand Challenges in Global Health, an initiative created by the Bill & Melinda Gates Foundation that seeks to engage creative minds across scientific disciplines — including those who have not traditionally taken part in health research — to work on solutions that could lead to breakthrough advances for those in the developing world. Jim Heath, Ph.D., co-founder and Board member, Integrated Diagnostics; Gilloon Professor, Caltech will pursue an innovative point-of-care diagnostics project, titled Protein Capture Agents with 40 oC shelf life for developing world point-of-care HIV-1 diagnostics.
Read MoreProteoMonitor / GenomeWeb | 28 October 2011 | Adam Bonislawski[subscription required]
Integrated Diagnostics Taking Aim at In Vivo Imaging, Therapeutics Markets with New PCC Reagents
Read MorePress Release | 26 October 2011
Protein-Catalyzed Capture Agents (PCCs) Designed Using “Click Chemistry” Show Promise for Broad Use in Diagnostics and Therapeutics
Data Demonstrating Synthetic Class of Site-Specific Binding Molecules is Published in the Journal of the American Chemical Society
SEATTLE — Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has created a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology (Caltech) using “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with unusual precision and stability. PCCs offer the promise of superior stability, lower cost and faster creation compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses. Data demonstrating the design and use of this synthetic class of site-specific binding molecules was recently published in the Journal of the American Chemical Society (JACS). In a separate release, Integrated Diagnostics also announced that it has licensed click chemistry from The Scripps Research Institute and appointed K. Barry Sharpless, Ph.D., the inventor of the process, as an advisor.
Read MorePress Release | 26 October 2011
Dr. Barry Sharpless, Nobel Laureate and Click Chemistry Pioneer, Joins Integrated Diagnostics as Advisor
SEATTLE — Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has signed a worldwide licensing agreement with The Scripps Research Institute, strengthening its growing network of partners. Under the license, the company will have access to “click chemistry,” a powerful chemical process developed by K. Barry Sharpless, Ph.D. Integrated Diagnostics concurrently announced that it has appointed Dr. Sharpless, who shared in the 2001 Nobel Prize for Chemistry, as an advisor. In a separate release, the company announced that it has used click chemistry in collaboration with the California Institute of Technology (Caltech) to create a synthetic class of diagnostic and therapeutic agents, with antibody-like properties.
Read More